Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma

@article{Tsang2011SyntheticLS,
  title={Synthetic Lethal Screen Identifies NF-$\kappa$B as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma},
  author={Patricia S. Tsang and A. Cheuk and Q. Chen and Y. Song and Thomas C. Badgett and Jun S. Wei and J. Khan},
  journal={BMC Cancer},
  year={2011},
  volume={12},
  pages={101 - 101}
}
BackgroundDespite aggressive multimodal treatments the overall survival of patients with high-risk neuroblastoma remains poor. The aim of this study was to identify novel combination chemotherapy to improve survival rate in patients with high-risk neuroblastoma.MethodsWe took a synthetic lethal approach using a siRNA library targeting 418 apoptosis-related genes and identified genes and pathways whose inhibition synergized with topotecan. Microarray analyses of cells treated with topotecan were… Expand
The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Triggering of Suicidal Erythrocyte Death by Topotecan
3-(2-Bromoethyl)-indole inhibits the growth of cancer cells and NF-κB activation
...
1
2
...

References

SHOWING 1-10 OF 48 REFERENCES
Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma
Proteasome inhibitors: antitumor effects and beyond
A selective small-molecule nuclear factor-κB inhibitor from a high-throughput cell-based assay for “activator protein-1 hits”
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)
  • P. Lara, K. Chansky, +8 authors D. Gandara
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2006
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
...
1
2
3
4
5
...